Clinical Trial Update: Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL) [Phase 1, Phase 2]

View source ↗

Summary

A frontline combination of linperlisib and obinutuzumab is being studied in a Phase 1/2 trial for marginal zone lymphoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Linperlisib (linperlisib)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: The First Hospital of Jilin University | Conditions: Lymphoma | Phase 1, Phase 2 | Status: RECRUITING